00:01
Let's move on to another case.
00:03
We have a 61 year old gentleman
who has stage 3B CKD
due to diabetic nephropathy
and hypertension,
So we're already kind of
thinking about where his GFR is
and what some of his
risk factors are.
00:15
On lab says serum creatinine is
2.1 milligrams per deciliter.
00:18
We can see that that's elevated
and his estimated GFR by
ckd-epi is 31 miles per minute.
00:25
His proteinuria is
estimated at 490 milligrams
by spot protein to
creatinine ratio.
00:31
He's on an Ace inhibitor,
but his blood pressure
isn't that well controlled
isn't about the 140s over 80s.
00:37
So the question is,
what is the most likely
outcome for this gentleman?
So what do you think?
You think he will progress to
stage 5 chronic kidney disease
and need dialysis or renal replacement
therapy within the next 3 years.
00:53
Do you think his creatinine
will stay the same
over the next three years?
What do you think He might die
from a cardiovascular event
like an acute coronary syndrome
or something of the like
within the next 3 years?
And you might be
surprised to know
that the correct choice is
actually the third choice
that this gentleman's
biggest risk
is dying from a
cardiovascular event.
01:15
And this really brings us to
our next part of the talk,
which is really talking about
consequences of having CKD.
01:22
One of the biggest ones that
I don't want you to forget
and again if you just take home
one point from this lecture,
I want you to remember
that when a patient
has chronic kidney disease,
the most significant
outcome or consequences
from having that is developing
cardiovascular disease.
01:37
So the majority of
patients with CKD
will die from cardiovascular
disease rather than
progress to end-stage
renal disease
and CKD and
cardiovascular disease
do share many risk factors.
01:49
But even when those
variables are factored out
there is an independent risk for
developing cardiovascular events
in chronic kidney
disease patients.
01:57
And that increase in risk of
having cardiovascular events
or disease is associated
with both a decrease in GFR
and also an increase
in proteinuria.
02:07
So this is a graph that really
illustrates the point of
what I'm talking about.
02:11
This is taken from the
Nephrology division at OHSU
and you can see on the y axis
we have percentage of cases
and on the x-axis we
have groups of patients
in either stage 2,
3 or 4 chronic kidney disease,
which you can see
designated by the GFR.
02:26
So what they did is
they followed patients
over a five-year period of time.
02:30
And they look to see how many
patients actually progressed
to the need of end
stage renal disease
or how many patients
actually died from
a cardiovascular event.
02:40
And what is so shocking to
look at here is if you see
again most patients
are actually dying
from a cardiovascular event
particularly focus on that stage
three chronic kidney disease.
02:52
Those are patients who
have GFR between 30 and 59
the bulk of those patients
we'll go on to die from
a cardiovascular event.
02:59
So again, it's going to
be important for us as
good primary caretakers and
as nephrologist to be able to
target the cardiovascular system
and modify those risk
factors for our patients.
03:11
Now another consequence
of having CKD
is actually hypertension.
03:15
So it's interesting
because most patients
with hypertension
or patients with hypertension can
manifest with chronic kidney disease,
but even patients who did not
have hypertension to begin with
can develop it because of
their chronic kidney disease.
03:27
So presents an about 80 to 85%
of patients who do have CKD
and the cost is
really multifactorial.
03:33
It includes sodium retention,
and increase in activity of the
renin-angiotensin-aldosterone system,
enhanced activity of the
sympathetic nervous system,
and mechanisms some secondary
hyperparathyroidism.
03:46
When our patients have
hyperparathyroidism,
they have a rise in the
intracellular calcium
and that can cause
vasoconstriction.
03:53
And then there's also some
imbalance on these mediators
they have impaired
nitric oxide synthesis
and endothelium
mediated vasodilation.
04:03
Another consequence of
having chronic kidney disease
is mineral bone disease.
04:07
So mineral bone disease refers
to issues with calcium
and phosphorus balance.
04:12
When you have a decrease in GFR,
it leads to a decrease in
urinary phosphorus excretion.
04:17
But remember our
parties are so elegant
they have out a regulatory
processes that can account for this.
04:22
So there's a compensatory increase
in a phosphatonin called FGF-23,
and what that does is it
increases phosphorus excretion
and attempts to maintain normal
serum phosporus concentration,
but the problem with that
is that FGF-23 also inhibits
1 Alpha hydroxylase,
remember this is an enzyme
at the specialized
tubular epithelial cells
and that is responsible
for activating vitamin D25
to its active form
calcitriol or 125D.
04:52
So if we don't have
that available or if
that's inhibited by FGF-23,
we now have a decrease in
the active form of vitamin D
or tells a trial.
05:00
So what's the consequence of
that having a decrease calcitriol
will reduce the intestinal
calcium absorption.
05:07
But again our body
being very elegant
we have to maintain normal
serum calcium at all time.
05:12
So we have a
mechanism to help that
PTH are parathyroid hormone
from our parathyroid gland
will increase in response
and then our patients
end up developing
secondary hyperparathyroidism,
in order to maintain that
normal serum calcium.
05:28
So once our patients develop
secondary hyperparathyroidism,
there is a significant
consequence to having that
Number 1. We worry about
vascular calcification.
05:36
Remember what's going on,
that parathyroid is actually
parathyroid hormone is
actually going to bone
to reabsorb
resort parts of that bone
so calcium and phosphorus
is liberated into the serum.
05:47
Now, we'd like it to go
where it's supposed to go.
05:49
But what ends up happening is
that can precipitate
on blood vessels
and people end up getting
vascular calcification.
05:55
The other major problem
that patients develop
is renal osteodystrophy
or bone disease
and this is actually manifesting by
a variety of different mechanisms,
patients can develop
osteomalacia,
which is defective
mineralisation.
06:08
They can have high
turnover bone disease,
which is actually shown here
in our image on the right
where they have periosteum
medical reabsorption.
06:15
So if that gets
really significant
patients can develop something
called osteitis fibrosa cystica
where they have this
peritrabecular fibrosis of bone.
06:25
Patients can also have
mixed uremic bone disease
where they have features
of both osteitis fibrosis
as well as osteomalacia,
and then finally patients actually
can develop something called
adynamic bone disease and
that's really iatrogenic.
06:37
That's something
that we can cause,
so when we try to
treat our patients
for having secondary
hyperparathyroidism,
meaning that they have those
elevated levels of high PTH.
06:47
We can give them an active
vitamin D analog like calcitriol,
but when we do that and we
suppress their PTH so much
those bones can actually
become quite brittle
and they have a decrease in
bone formation and turnover
and that can lead to
trochanteric fractures.
07:02
So we have to be very careful
when it comes to
mineral bone disease
and it's really an area of
nephrology right now that's exploding
with new information.
07:10
So stay tuned.
07:12
Another consequence of having
chronic kidney disease is anemia.
07:16
Anemia is defined by hemoglobin
of less than 13 grams
per deciliter for men
and postmenopausal women
and less than 12 grams per
deciliter for premenopausal women.
07:27
So typically what happens
is our kidney specialized
fibroblasts in the kidney
are actually responsible
for making a hormone
called erythropoietin.
07:36
Erythropoietin goes
to the bone marrow
and is responsible for
generating new red blood cells
and putting them out
into the circulation.
07:42
What's interesting,
Is that about 90% of
patients with the GFR
of less than 30 mils per minute
will manifest with
having anemia,
again, why is this happening?
Because of the fact
that there's decreased
erythropoietin or EPO production
because as kidney function
decreases those fibroblasts
that actually generate Epo
or erythropoietin are
actually getting damaged.
08:03
So our patients
manifest sometimes
with very significant anemia.